Ginkgo biloba and Acetazolamide Prophylaxis for Acute Mountain Sickness A Randomized, Placebo-Controlled Trial

Chow T, Browne V, Heileson HL, et al. — Mon, 14 Feb 2005 00:00:00 GMT

Background

Acute mountain sickness (AMS) commonly occurs when unacclimatized individuals ascend to altitudes above 2000 m. Acetazolamide and Ginkgo biloba have both been recommended for AMS prophylaxis; however, there is conflicting evidence regarding the efficacy of Ginkgo biloba use. We performed a randomized, placebo-controlled trial of acetazolamide vs Ginkgo biloba for AMS prophylaxis.

Methods

We randomized unacclimatized adults to receive acetazolamide, Ginkgo biloba, or placebo in double-blind fashion and took them to an elevation of 3800 m for 24 hours. We graded AMS symptoms using the Lake Louise Acute Mountain Sickness Scoring System (LLS) and compared the incidence of AMS (defined as LLS score ≥3 and headache).

Results

Fifty-seven subjects completed the trial (20 received acetazolamide; 17, Ginkgo biloba, and 20, placebo). The LLS scores were significantly different between groups; the median score of the acetazolamide group was significantly lower than that of the placebo group (P = .01; effect size, 2; and 95% confidence interval [CI], 0 to 3), unlike that of the Ginkgo biloba group (P = .89; effect size, 0; and 95% CI, −2 to 2). Acute mountain sickness occurred less frequently in the acetazolamide group than in the placebo group (effect size, 30%; 95% CI, 61% to −15%), and the frequency of occurrence was similar between the Ginkgo biloba group and the placebo group (effect size, −5%; 95% CI, −37% to 28%).

Conclusions

In this study, prophylactic acetazolamide therapy decreased the symptoms of AMS and trended toward reducing its incidence. We found no evidence of similar efficacy for Ginkgo biloba.

JAMA Internal Medicine: Salivary Gland Disorders Topic Collection

Ginkgo biloba and Acetazolamide Prophylaxis for Acute Mountain Sickness A Randomized, Placebo-Controlled Trial